drug
eptinezumab
Marketedupdated 4mo agoby H. Lundbeck AS
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
Trials studying eptinezumab
- phase3A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- phase3A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- phase3Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension
- phase3A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
- —Facilitators and Barriers to Eptinezumab Administration in Thailand
- phase4A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
- phase4A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
- phase3Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
News(4)
- Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trialsSlate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical data on its lead c…fiercebiotech · 10d ago
- FDA criticizes Lundbeck for webpages on migraine treatment VyeptiThe FDA has chastised Lundbeck Seattle Biopharmaceuticals for two promotional webpages that made allegedly inflated claims regarding the efficacy of its migraine drug. In an untitled letter sent la…endpoints · 1mo ago
- Study data convince Lundbeck to push new migraine drug forwardA possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.biopharma_dive · 2mo ago
- A migraine drugmaker heads to the public markets through reverse mergerMentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.biopharma_dive · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that